RecruitingNot ApplicableNCT07453823

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight

The Effect of a Synbiotic on Intestinal Barrier Function and Microbiota Modulation in Middle-aged to Elderly Individuals With Excessive Body Weight: a Randomized, Double-blind, Placebo-controlled Study


Sponsor

Chr Hansen - part of Novonesis

Enrollment

90 participants

Start Date

Mar 18, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The study is a single-center, randomized, double-blind, placebo-controlled study in middle-aged to elderly adults with excessive body weight. The study includes an 8-week intervention period followed by a 2-week follow-up period. The study will evaluate the effect of a synbiotic consisting of two probiotic strains and a prebiotic. The aim is to investigate the effect of the synbiotic on modulating the gut microbiota and improving markers of gastrointestinal permeability and integrity and gastrointestinal discomfort.


Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Placebo and Synbiotic for people with gastrointestinal microbiome (focus) and gastrointestinal symptoms. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTSynbiotic

Synbiotic \- Given daily for 56 days

DIETARY_SUPPLEMENTPlacebo

Placebo \- Given daily for 56 days


Locations(1)

Atlantia Clinical Trials Ltd

Cork, Blackpool, Ireland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07453823


Related Trials